Physician
Nephrology
Dr. William L. Macias, MD
William L. Macias, MD practices Nephrology. William Macias is a published doctor. He has 57 publications published. The most current publication "Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men."
Publications
- Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized...
- Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON-TIMI 38 Substudy.
- Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.
- Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
- Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock.
- Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever.
- Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis.
- Activated protein C: do more survive?
- Early changes in organ function predict eventual survival in severe sepsis.
- Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure.
- Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis.
- Severe protein C deficiency predicts early death in severe sepsis.
- Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
- A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis.
- Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.
- Urea kinetics during continuous hemofiltration.
- NaCl transport by Madin Darby canine kidney cyst epithelial cells.
- Extracorporeal therapy requirements for patients with acute renal failure.
- Dialysis prescription and kinetics in acute renal failure.
- Renal replacement therapy quantification in acute renal failure.
- The role of renal replacement therapy quantification in acute renal failure.
- Lidocaine in continuous venovenous hemofiltration.
- Efficacy of convective removal of plasma mediators of endotoxic shock by continuous veno-venous hemofiltration.
- Plasma protein adsorption to highly permeable hemodialysis membranes.
- Azotemia control by extracorporeal therapy in patients with acute renal failure.
- Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration.
- Quantification of creatinine kinetic parameters in patients with acute renal failure.
- Effects of continuous venovenous hemofiltration on cardiopulmonary function in a porcine model of endotoxin-induced shock.
- Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men.
- Membrane adsorption of beta 2-microglobulin: equilibrium and kinetic characterization.
- Antithrombin and heparin may limit the activation of Protein C.
- Activated protein C levels in patients with severe sepsis: rebuttal.
- A comparison of metabolic control by continuous and intermittent therapies in acute renal failure.
- Continuous venovenous hemofiltration: an alternative to continuous arteriovenous hemofiltration and hemodiafiltration in acute renal failure.
- Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance.
- Impact of the nutritional regimen on protein catabolism and nitrogen balance in patients with acute renal failure.
- The development of drotrecogin alfa (activated) for the treatment of severe sepsis.
- The value of innovation.
- Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
- Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
- Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
- Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
- New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).
- Management of early acute renal failure: focus on post-injury prevention.
- Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis.
- Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early t...
- Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions.
- Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).
- International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
- Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
- Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome.
- International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.
- Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improve...
- Cytochrome p-450 polymorphisms and response to clopidogrel.
- Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
- Activated protein C and acute kidney injury: Selective targeting of PAR-1.
Schools
Indiana University School of Medicine
Doctors Specialties
- Critical Care Medicine
- Nephrology
Accepted Insurances
Helpful Reviews
Similar Doctors
|
Dr. Robert W. Weller Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sharon M. Moe, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Melissa D. Anderson, MD |
|
|
Dr. Stephen F. Wintermeyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian S. Decker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Landon E. Dickson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael T. Eadon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lisa M. McGuire, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William H. Dick, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert L. Bacallao, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Douglas R. Maxwell, MD |
|
|
Dr. Areeba T. Jawed, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Houssam A. Oueini, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory D. Ruppel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christian Pelte, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Terence Samuel, MD |
|
|
Dr. Anupama Mohanram, MD |
|
Dr. Charles B. Carter Sr., MD
This Doctor is OpenDoctor Recommended.
|